Modulators of amyloid aggregation
Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compounds of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.
1. An amyloid modulator compound having the structure:
wherein Xaa is an amyloidogenic protein, or peptide fragment thereof, of at least 4 amino acid residues in length and A is a modifying group comprising a cyclic, heterocyclic or polycyclic group, covalently attached to the carboxy-terminus of the amyloidogenic protein, or peptide fragment thereof, such that the compound modulates the aggregation of natural amyloid proteins or peptides when contacted with the natural amyloidogenic proteins or peptides, wherein Xaa is not calcitonin.
2. An amyloid modulator compound comprising the structure:
wherein Xaa is an amyloidogenic protein, or peptide fragment thereof, of at least 4 amino acid residues in length and A is a modifying group comprising a cyclic, heterocyclic or polycyclic group, covalently attached to the α-amino group at the amino-terminus of the amyloidogenic protein, or peptide fragment thereof, such that the compound modulates the aggregation of natural amyloid proteins or peptides when contacted with the natural amyloidogenic proteins or peptides, wherein Xaa is selected from the group consisting of transthyretin (TTR), prion protein (PrP), atrial natriuretic factor (ANF), kappa light chain, lambda light chain, amyloid A, procalcitonin, cystatin C, β2 microglobulin, ApoA-J, gelsolin, fibrinogen and lysozyme.
3. The compound of claim 2 , which inhibits aggregation of natural amyloidogenic proteins or peptides when contacted with the natural amyloidogenic proteins or peptides.
4. The compound of claim 3 , which inhibits aggregation of natural amyloidogenic proteins or peptides when contacted with a molar excess amount of natural amyloidogenic proteins or peptides.
5. The compound of claim 1 or 2 , wherein the modifying group contains a cis-decalin group.
6. The compound of claim 5 , wherein the modifying group contains a cholanoyl structure.
7. The compound of claim 6 , wherein the modifying group is a cholyl group.
8. The compound of claim 1 or 2 , wherein the modifying group comprises a biotin-containing group, a diethylene-triaminepentaacetyl group, a (−)-menthoxyacetyl group, a fluorescein-containing group or an N-acetylneuraminyl group.
9. The compound of claim 1 , which inhibits aggregation of natural amyloidogenic proteins or peptides when contacted with the natural amyloidogenic proteins or peptides.
10. The compound of claim 1 , which is further modified to alter a pharmacokinetic property of the compound.
11. The compound of claim 1 , which is further modified to label the compound with a detectable substance.
12. The compound of claim 1 , wherein the amyloidogenic protein, or peptide fragment thereof, is selected from the group consisting of transthyretin (TTR), prion protein (PrP), islet amyloid polypeptide (IAPP), atrial natriuretic factor (ANF), kappa light chain, lambda light chain, amyloid A, procalcitonin, cystatin C, β2 microglobulin, ApoA-J, gelsolin, fibrinogen and lysozyme.
13. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or 2 and a pharmaceutically acceptable carrier.
14. A method for altering aggregation of natural amyloid proteins or peptides, comprising contacting the natural amyloid proteins or peptides with the compound of claim 1 or 2 such that aggregation of the natural amyloid proteins or peptides is altered.
15. A method for detecting aggregation of natural amyloid proteins or peptides, comprising:
(1) modifying the compound of claim 1 or 2 with a detectable substance; and
(2) contacting a biological sample with the modified compound such that aggregation of the natural amyloid proteins or peptides in the sample is detected.
16. The method of claim 15 , wherein the compound is administered to a subject to detect aggregation of the natural amyloid proteins or peptides in the subject.
17. The method of claim 16 , wherein the compound is labeled with radioactive iodine or technetium.
18. A method for treating a subject for a disorder associated with amyloidosis, comprising:
administering to the subject a therapeutically or prophylactically effective amount of the compound of claim 2 such that the subject is treated for a disorder associated with amyloidosis.
19. A method for treating a subject for a disorder associated with amyloidosis, comprising:
administering to the subject a therapeutically or prophylactically effective amount of the compound of claim 1 such that the subject is treated for a disorder associated with amyloidosis.
20. The method of claim 19 , wherein the disorder is selected from the group consisting of familial amyloid polyneuropathy, familial amyloid cardiomyopathy, isolated cardiac amyloid, systemic senile amyloidosis, scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, adult onset diabetes, insulinoma, isolated atrial amyloidosis, idiopathic amyloidosis, myeloma or macroglobulinemia-associated amyloidosis, primary localized cutaneous nodular amyloidosis associated with Sjogren's syndrome, reactive amyloidosis, familial Mediterranean Fever and familial amyloid nephropathy with urticaria and deafness, hereditary cerebral hemorrage with amyloidosis of Icelandic type, amyloidosis associated with long term hemodialysis, hereditary non-neuropathic systemic amyloidosis, familial amyloidosis of Finnish type, amyloidosis associated with medullary carcinoma of the thyroid, fibrinogen-associated hereditary renal amyloidosis and lysozyme-associated hereditary systemic amyloidosis.